[Current role of hormone replacement therapy in the prevention of postmenopausal osteoporosis: gynecologic point of view].
Hormonal Replacement Therapy (HRT) of the menopause has already proved to be effective in preventing bone loss and reducing the risk of fractures in postmenopausal women. Up until 2002, HRT was widely proposed and prescribed by French practitioners, in particular with regard to the prevention of osteoporosis. The results of two major studies, one American, the Women's Health Initiative (WHI) Study, and the other British, the Million Women Study (MWS), published in July 2002 and August 2003, have called into question the hitherto favourable benefits/risks ratio of HRT after finding an increased incidence of breast cancer and heart disease amongst women undergoing this treatment. Following these studies, the European and French health authorities have issued new recommendations regulating and restricting the use of HRT with a drastic restriction on the indications for its use in the prevention of osteoporosis. These new recommendations are the subject of controversy and pose new problems for practitioners.
Tamborini
A
A
Centre de surveillance et traitement de la ménopause, service de gynécologie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France. alain.tamborini@wanadoo.fr
Ruiz
J C
JC
D000368:Aged; D001943:Breast Neoplasms / Q000139:chemically induced / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000517:prevention & control; D002986:Clinical Trials as Topic; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000150:complications / Q000517:prevention & control*; D017698:Postmenopause; D012307:Risk Factors